Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma

Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma

Current treatments for osteosarcoma, combining conventional polychemotherapy and surgery, make it possible to attain a five-year survival rate of 70% in affected individuals. The presence of chemoresistance and metastases significantly shorten the patient’s lifespan, making identification of new the...

Full description

Bibliographic Details
Main Authors: Javier Muñoz-Garcia, Jorge William Vargas-Franco, Bénédicte Brounais-Le Royer, Denis Cochonneau, Jérôme Amiaud, Marie-Françoise Heymann, Dominique Heymann, Frédéric Lézot
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
osteosarcoma
RANKL
endothelin
bone protection
metastases
Online Access:https://www.mdpi.com/2072-6694/14/7/1765

Internet

https://www.mdpi.com/2072-6694/14/7/1765

Similar Items